Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison

Journal of Medical Economics, Journal Year: 2022, Volume and Issue: 25(1), P. 679 - 690

Published: May 16, 2022

To compare the efficacy of tezepelumab with other approved biologics via indirect treatment comparisons (ITCs) in patients aged ≥ 12 years severe uncontrolled asthma.Data from randomized controlled trials (RCTs) identified a systematic literature review were synthesized using two different ITC approaches: network meta-analysis (NMA) and simulated comparison (STC). Outcomes interest annualized asthma exacerbation rate (AAER) AAER for exacerbations leading to hospitalization. address potential heterogeneity between study populations, various subgroup analyses performed NMA (based on blood eosinophil count, fractional exhaled nitric oxide level, presence allergic asthma), STC, models adjusted effect modifiers. Sensitivity assess impact design (exclusion non-placebo-controlled studies non-phase 3 or 4 studies). Results reported as ratios (RRs) 95% credible/confidence intervals ranking statistics computed NMAs.Sixteen RCTs included at least one ITCs. All (tezepelumab, dupilumab, benralizumab, mepolizumab, reslizumab, omalizumab) had similar efficacy, no statistically significant RRs either outcome; however, was favorably associated numerically lower AAERs ranked first both types outcome. This trend consistent sensitivity analyses. As primary NMA, STC results did not demonstrate any differences biologics, but point estimates favorable towards tezepelumab.Heterogeneity observed among eligibility criteria clinically important patient characteristics; findings is expected be low, based consistency across analyses.Findings ITCs (NMA STC) support use broad population phenotype.

Language: Английский

---

Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis

The Journal of Allergy and Clinical Immunology In Practice, Journal Year: 2023, Volume and Issue: 11(5), P. 1475 - 1484.e20

Published: Jan. 28, 2023

Language: Английский

---

Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types

Journal of Asthma and Allergy, Journal Year: 2024, Volume and Issue: Volume 17, P. 219 - 236

Published: March 1, 2024

Abstract: Asthma is a heterogeneous inflammatory disease of the airways, affecting many children, adolescents, and adults worldwide. Up to 10% people with asthma have severe disease, associated higher risk hospitalizations, greater healthcare costs, poorer outcomes. Patients generally require high-dose inhaled corticosteroids additional controller medications achieve control; however, patients remain uncontrolled despite this intensive treatment. The treatment has improved understanding pathways phenotypes as well advent targeted biologic therapies. Tezepelumab, monoclonal antibody, blocks thymic stromal lymphopoietin, an epithelial cytokine that multifaceted effects on initiation persistence inflammation pathophysiology. Unlike other treatments, tezepelumab demonstrated efficacy across phenotypes, magnitude varying by phenotype. Here we describe anti-inflammatory most relevant asthma. Across clinical studies, reduced annualized exacerbation rates versus placebo 63– 71% in eosinophilic asthma, 58– 68% allergic 67– 34– 49% type 2-low 31– 41% oral corticosteroid-dependent Furthermore, all these reducing exacerbations requiring hospitalizations or emergency department visits placebo. In who commonly multiple drivers may modulate airway more extensively, available biologics block only specific downstream components cascade. Plain Language Summary: characterized immune response leading inflammation. People react different triggers develop types protein called lymphopoietin (TSLP) plays important role leads signs symptoms TSLP released lining triggers, driving chain reaction, narrowing tightening, increased inflammation, worsening symptoms, attack. Tezepelumab antibody (a protein) prevents from attaching its receptor, thereby blocking activity, symptoms. add-on medicine for aged 12 years older not controlled their current medicines. article, discuss how work example T2-low We also effective types, through reduction attacks improvement lung function, symptom control, quality life, fewer Keywords: exacerbations, eosinophilic, allergic, 2, corticosteroid-dependent, hyperresponsiveness

Language: Английский

---

What has been learned by cytokine targeting of asthma?

Journal of Allergy and Clinical Immunology, Journal Year: 2022, Volume and Issue: 150(2), P. 235 - 249

Published: Aug. 1, 2022

Language: Английский

---

Exhaled Biomarkers for Point-of-Care Diagnosis: Recent Advances and New Challenges in Breathomics

Micromachines, Journal Year: 2023, Volume and Issue: 14(2), P. 391 - 391

Published: Feb. 4, 2023

Cancers, chronic diseases and respiratory infections are major causes of mortality present diagnostic therapeutic challenges for health care. There is an unmet medical need non-invasive, easy-to-use biomarkers the early diagnosis, phenotyping, predicting monitoring responses these disorders. Exhaled breath sampling attractive choice that has gained attention in recent years. nitric oxide measurement used as a predictive biomarker response to anti-eosinophil therapy severe asthma paved way other exhaled biomarkers. Advances laser nanosensor technologies spectrometry together with widespread use algorithms artificial intelligence have facilitated research on volatile organic compounds olfaction systems develop new We aim provide overview advances measurements emphasis applicability their point-of-care tool.

Language: Английский

---

Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma

Allergology International, Journal Year: 2022, Volume and Issue: 72(1), P. 24 - 30

Published: Dec. 2, 2022

Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades. Tezepelumab, human IgG2 monoclonal antibody inhibits binding TSLP to receptor, latest biologic for asthma. To evaluate efficacy mechanism tezepelumab asthma, PATHWAY, NAVIGATOR, NOZOMI, UPSTREAM, CASCADE, SOURCE, DESTINATION studies have been conducted. These results suggested broad-target biologic, which expected be effective patients with poorly controlled moderate severe asthma regardless phenotype, although its oral corticosteroids-dependent biological non-type long-term safety remain unknown. In this review, we summarize clinical trials discuss differences between other biologics.

Language: Английский

---

Asthma in the era of COVID-19

Respiratory Medicine, Journal Year: 2023, Volume and Issue: 218, P. 107373 - 107373

Published: Aug. 10, 2023

Language: Английский

---

A comparison of the effectiveness of biologic therapies for asthma

Annals of Allergy Asthma & Immunology, Journal Year: 2022, Volume and Issue: 130(5), P. 595 - 606

Published: Dec. 20, 2022

Language: Английский

---

Tezepelumab: An Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody for the Treatment of Asthma

Immunotherapy, Journal Year: 2023, Volume and Issue: 15(17), P. 1435 - 1447

Published: Sept. 19, 2023

Asthma is a common chronic respiratory disease in which epithelial cytokines and airway inflammation play critical pathophysiological roles. Thymic stromal lymphopoietin (TSLP), an cytokine, central the initiation persistence of asthma. Tezepelumab human immunoglobulin G2λ (IgG2λ) monoclonal antibody developed for treating moderate-to-severe asthma by specifically binding to TSLP preventing its receptor on inflammatory cells. In this narrative review, we describe results clinical trials that evaluated pharmacokinetics, pharmacodynamics, efficacy safety tezepelumab patients with We also introduce ongoing as well future investigating use other indications.Asthma long-term causes cells lung. One (proteins) involved called thymic (TSLP). This cytokine produced epithelium, layer covering tract lungs, where it activates new drug blocks activity lungs helps reduce symptoms, such coughing breathlessness. article, investigated how works, safety, people moderate or severe are now underway asthma, allergies diseases.

Language: Английский

---

Head‐To‐Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?

Allergy, Journal Year: 2025, Volume and Issue: unknown

Published: March 29, 2025

We performed an in-depth appraisal of indirect head-to-head comparisons biologics approved for asthma, including anti-IL5/5Rα (mepolizumab, benralizumab), anti-IL4Rα (dupilumab), anti-TSLP (tezepelumab) and anti-IgE (omalizumab), which was neither a systematic review nor meta-analysis. A crude evaluation 95% CI's rate ratios excluded unity revealed greater overall reductions in annualised exacerbations with dupilumab versus either mepolizumab or benralizumab also tezepelumab benralizumab. Furthermore patients eosinophils ≥ 300/μL exacerbation rates were lower tezepelumab, benralizumab; eosinophils< 150/μL dupilumab. For lung function, no differences FEV1 response observed between drugs where there considerable heterogeneity overlapping CI's. Dupilumab superior to oscillometry-derived peripheral resistance compliance, as well attenuation mannitol airway hyperresponsiveness. There asthma control quality life scores the effect sizes small, along wide overlaps is unmet need prospective pragmatic randomised controlled trials directly compare biologics, especially assess clinical remission both type 2 high low patients. Real-life studies might evaluate complete different include outcomes such inhaled corticosteroid sparing, small airways dysfunction using oscillometry, abolition hyperresponsiveness mucus plugging remodelling wall thickening imaging.

Language: Английский

---